Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma

Neurosurgical Focus

Volumn 37, Issue 6, 2014, Pages

  Agnihotri, Sameer ^a   Aldape, Kenneth D ^c   Zadeh, Gelareh ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Glioblastoma; IDH1; Tumor metabolism

Indexed keywords

ISOCITRATE DEHYDROGENASE;

BRAIN NEOPLASMS; ENZYMOLOGY; GENETICS; GLIOBLASTOMA; GLIOMA; HUMAN; METABOLISM;

BRAIN NEOPLASMS; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE;

EID: 84916881458     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.9.FOCUS14505     Document Type: Article

References (79)

1. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al: Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 123:3659-3663, 2013
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
3. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al: Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453-1455, 2011
4. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al: Mesenchymal differentiation mediated by NF-kB promotes radiation resistance in glioblastoma. Cancer Cell 24:331-346, 2013
5. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al: The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25:2594-2609, 2011
6. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11, 2009
7. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51, 2007
8. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
9. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al: Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241-252, 2011
10. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254, 2010
11. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012 (Erratum in Cancer Discov 2:960, 2012)
12. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al: 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624-629, 2012
13. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181-186, 2008
14. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009
15. Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, et al: ML309: a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. May 8, 2013. Probe Reports from the NIH Molecular Libraries Program. (http://www. ncbi.nlm.nih.gov/books/NBK153220/) [Accessed October 12, 2014]
16. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, et al: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795, 2009
17. Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, et al: A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22:2339-2355, 2012
18. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al: Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 4:116ra115, 2012
19. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010
20. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1, 2013
21. Geisbrecht BV, Gould SJ: The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527-30533, 1999
22. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, et al: Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140:678-691, 2010
23. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, et al: IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18:2490-2501, 2012
24. Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, et al: In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A 111:5248-5253, 2014
25. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718, 2010
26. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474, 2009
27. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874, 2004
28. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560-1566, 2010
29. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al: Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-722, 2012
30. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, et al: Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73:496-501, 2013
31. Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, et al: 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS ONE 6:e16812, 2011
32. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al: Mutational analysis reveals the origin and therapydriven evolution of recurrent glioma. Science 343:189-193, 2014
33. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, et al: Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927-932, 2013
34. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al: Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-105, 2012
35. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al: Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708-2714, 2010
36. Kleihues P, Cavanee WK (eds): World Health Organization Classification of Tumors. Pathology and Genetics: Tumours of the Nervous System. Lyon: IARC Press, 2000
37. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al: Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-488, 2012
38. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD: Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A 107:14075-14080, 2010
39. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109, 2007
40. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, et al: Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 8:e1002772, 2012
41. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478, 2012
42. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34, 2010
43. Michelakis ED, Webster L, Mackey JR: Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989-994, 2008
44. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007, 2009
45. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al: Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488:49-56, 2012
46. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
47. Ohgaki H, Burger P, Kleihues P: Definition of primary and secondary glioblastoma-response. Clin Cancer Res 20:2013, 2014 (Letter)
48. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445-1453, 2007
49. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56, 2004
50. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al: C11orf95-RELA fusions drive oncogenic NF-kB signalling in ependymoma. Nature 506:451-455, 2014 (Erratum in Nature 508:554, 2014)
51. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
52. Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, et al: D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathol Commun 2:19, 2014
53. Reifenberger G, Louis DN: Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111-126, 2003
54. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al: Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 108:3270-3275, 2011
55. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al: Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43-48, 2012
56. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626-630, 2013
57. Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, et al: Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol 16:914-923, 2014
58. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
59. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, et al: D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26:2038-2049, 2012
60. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, et al: IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656-659, 2012
61. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231, 2012
62. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70:8981-8987, 2010
63. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al: Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110:4009-4014, 2013
64. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
65. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437, 2012
66. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-483, 2012
67. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604, 2010
68. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
69. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, et al: Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 103:267-275, 2002
70. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153, 2009
71. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol 117:653-656, 2009
72. Wolf A, Agnihotri S, Guha A: Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1:552-562, 2010
73. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208:313-326, 2011
74. Wolf A, Agnihotri S, Munoz D, Guha A: Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis 44:84-91, 2011
75. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251-253, 2012
76. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30, 2011
77. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
78. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602-612, 2013
79. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al: Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265, 2009